Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CC-90001 for non-alcoholic fatty liver disease and liver cirrhosis was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• CC-90001

Snippet

Sponsor: Celgene | Conditions: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis | Phase 2 | Status: TERMINATED | Results posted: 2023-06-07